<DOC>
	<DOC>NCT00262249</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The purpose of the trial is to compare the effect of NorditropinÂ® using different dosing regimens in children suspected of growth hormone deficiency.</brief_summary>
	<brief_title>Effect of Growth Hormone in Children With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Clinically suspected GHD Height &lt; 2.0 SDS Serum IGFI less than or equal to 1.0 SDS Bone age less than or equal to 9 years for boys and less than or equal to 7 years for girls. Puberty Tanner Stage I Previous use of growth hormone Growth retardation attributable to causes other than GHD (e.g. inborn errors of metabolism, primary bone disease, chromosomal disorders, etc.) Intrauterine growth retardation: birth weight &lt; 3rd percentile. Administration of other growthaltering medications. Evidence of any malignancy or intracranial tumors.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>